Advanced Practice Providers Treat Significantly More of their Multiple Sclerosis Patients with Monoclonal Antibody Disease-Modifying Therapies Compared to Neurologists in the US
Market access restrictions for these high efficacy therapies may be hindering their ability to optimally treat their clinically complex, relapsing patients, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 15, 2017 /PRNewswire/ — Advanced practice providers (APPs), including nurse practitioners and physician assistants, play an important role as […]
In the CKD-MBD Market, OPKO’s Rayaldee Continues to Struggle While Keryx’s Auryxia Gains Momentum, According to Latest Quarterly Update from Spherix Global Insights
Amgen’s Parsabiv, having finally received a J-code effective January 2018, is poised for rapid uptake in the dialysis market, not only off-setting Amgen’s own Sensipar but expanding the calcimimetic-treated population overall Download Report Overview EXTON, Pa., Nov. 14, 2017 /PRNewswire/ — A survey of over 200 US nephrologists fielded in late September indicates that, while […]
The Renal Anemia Market is on the Cusp of Change Beginning with the FDA Approval of Keryx Biopharmaceutical’s Auryxia for the Treatment of Iron Deficiency Anemia (IDA) in Adults with Chronic Kidney Disease, Not on Dialysis (CKD-ND)
New indication should bolster sales of Auryxia according to the latest reports from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 7, 2017 /PRNewswire/ — Earlier today Keryx announced the second approval for Auryxia (ferric citrate) to treat iron deficiency anemia in patients with chronic kidney disease. It is the first oral iron product […]
Janssen’s Stelara and Novartis’ Cosentyx Take the Cake When Psoriasis Patients Switch between Biologic/Otezla Agents, According To a Recent Audit of Nearly 1,000 Recently Switched Psoriasis Patients Conducted by Spherix Global Insights
Over one in five psoriasis patients are reported to switch between biologics or Celgene’s Otezla to a different brand within a given year Download Report Overview EXTON, Pa., October 31, 2017 /PRNewswire/ — Spherix Global Insights announces the release of RealWorld Dynamix™: Biologic and Otezla Switching in Psoriasis, a project undertaken in collaboration with 201 […]
US Rheumatologists Report that Use of Biologic/JAK Monotherapy in Rheumatoid Arthritis is Greatest for Pfizer’s Xeljanz, Roche/Genentech’s Actemra, and Sanofi/Regeneron’s Recently Launched Kevzara
Use of biologic/JAK monotherapy is primarily driven by adequate patient response on monotherapy, tolerability issues with traditional DMARDs, or comorbidities preventing use, according to recent findings from Spherix Global Insights Download Report Overview EXTON, Pa., October 23, 2017 /PRNewswire/ — Despite rheumatologists (n=102) reports of increased monotherapy over the past year, most feel that methotrexate […]
US Rheumatologists Teed Up for Rapid Adoption of BMS’ Orencia in Psoriatic Arthritis, Though the Real Game Changer Could Come with the Approval of Pfizer’s Xeljanz
Half of all surveyed rheumatologists agree a new oral small molecule would be of greater use in psoriatic arthritis than any additional alternative mechanism of action biologic, according to recent findings from Spherix Global Insights Download Report Overview EXTON, Pa., Oct. 20, 2017 /PRNewswire/ — At approximately three months post-launch, one-third of sampled rheumatologists (n=102) […]
Despite Rheumatologist Reports that BMS’ Orencia is Their Preferred Non-TNF Agent for Treating Rheumatoid Arthritis, Pfizer’s Xeljanz Provides Steep Competition in Actual Switching Patterns
Patient Requests are a Key Driver Behind Switching Brands in Rheumatoid Arthritis, according to a Recently Released Study by Spherix Global Insights Download Report Overview EXTON, Pa., Oct. 16, 2017 /PRNewswire/ — Spherix Global Insights announces the release of the 2017 edition of RealWorld Dynamix™: Biologic and JAK Switching in RA, a project undertaken in […]
FDA Approval of Mylan’s Glatiramer Acetate Will Turn the Payer Pressure On for Teva’s Copaxone and Sandoz’s Glatopa
While Copaxone brand loyalists and therapeutic equivalence concerns remain, the preference for three-times-weekly dosing will diminish reluctance to initiate generics, according to the most recent quarterly update by Spherix Global Insights Download Report Overview EXTON, Pa., Oct. 4, 2017 /PRNewswire/ — With the FDA approval and imminent shipping of Mylan’s generic glatiramer acetate (GA 20mg […]
Analysis of Over 1000 Psoriatic Arthritis (PsA) Patients Reveals Large Candidate Pool for Pfizer’s Xeljanz, BMS’ Orencia, and Eli Lilly’s Taltz
According to Spherix Global Insights, the analysis indicates an increase in biologic switching rates compared to the prior year with a growing movement away from TNF cycling, opening doors for earlier use of alternative mechanism agents Download Report Overview EXTON, Pa., Sept. 26, 2017 /PRNewswire/ — According to a new sub-analysis of PsA patients recently […]
First-in-Class PPMS Indication Fueling Much of the Adoption of Genentech’s Ocrevus, but Insurance Coverage Issues Could be a Looming Stumbling Block
As previously predicted, Ocrevus trial and share has increased significantly, positioning the new market entrant as second only to Biogen’s Tysabri in the mAb DMT class, according to the most recent quarterly update by Spherix Global Insights Download Report Overview EXTON, Pa., Sept. 19, 2017 /PRNewswire/ — Four months post-launch, keeping pace with neurologists’ previous […]
